Partial
Mostly Aligned
Patient Risk:
Low
Summary
The submitted claims largely cover dosing considerations and several safety monitoring aspects but omit key contraindications, boxed warnings, pregnancy/pediatric safety, and comprehensive monitoring guidance, resulting in partial alignment with the label.
Category Scores
MonitoringRecommendations
60
MonitoringRecommendations
60
Accurate Statements
Methotrexate side effects vary by dose, administration route (oral, injection, or IV), and patient factors like age or kidney function.
2.3, 2.4, 2.5, 8.6, 8.7, 5.3, 5.4, 5.5, 7.1
Lung issues like pneumonitis can onset acutely (days) or chronically (months).
5.6
Liver toxicity builds over weeks to months with cumulative use, detected via blood tests.
5.5
Folic acid supplements reduce early GI symptoms without delaying detection of others.
2.3, 5.10
Alcohol or NSAIDs accelerate liver risks.
5.5, 7.1
Liver tests start at baseline.
5.5
Liver tests repeat every 1-3 months.
5.5
Report severe nausea immediately.
2.1
Report unusual bleeding immediately.
2.1
Report shortness of breath immediately.
2.1
Delays in reporting can worsen outcomes.
2.1
Rheumatoid arthritis/psoriasis (low weekly dose): GI effects in 1-3 days.
2.3
Rheumatoid arthritis/psoriasis (low weekly dose): hematologic effects in 1-2 weeks.
5.3
Unsupported Statements
Serious effects like bone marrow suppression can take 1-2 weeks.
No explicit 1-2 week onset timing in the provided label citations.
Nausea, vomiting, and mouth sores often start 24-48 hours after dosing.
No explicit onset times in the supplied citations.
Nausea, vomiting, and mouth sores peak around day 2-3 for weekly low-dose regimens used in rheumatoid arthritis.
No explicit peak timing for RA dosing in the supplied citations.
Fatigue and mild liver enzyme elevations may emerge within 3-7 days.
No explicit 3-7 day onset in the provided citations.
Blood count drops usually occur 7-14 days post-dose.
Timing not explicitly specified in provided label citations.
Blood count drops usually resolve 1-2 weeks after stopping.
Resolution timing not explicitly specified in provided citations.
Higher doses (e.g., cancer chemotherapy) cause faster effects—nausea in hours.
No explicit hours onset claim in provided citations.
Higher doses (e.g., cancer chemotherapy) cause faster effects—myelosuppression in 4-7 days.
No explicit 4-7 day timing in provided citations.
Cancer (high dose): Acute in hours.
No explicit hours onset claim in provided citations.
Cancer (high dose): Delayed in 1-3 weeks.
No explicit 1-3 week onset claim in provided citations.
Rheumatoid arthritis/psoriasis (low weekly dose): GI effects in 1-3 days.
Not clearly supported by provided citations.
Rheumatoid arthritis/psoriasis (low weekly dose): hematologic effects in 1-2 weeks.
Not clearly supported by provided citations.
Contradictions
Important Omissions
Pregnancy contraindication and boxed warnings not addressed; fetal risk statements not provided.
Importance:
High
Pediatric safety guidance not addressed; pediatric dosing/safety data not referenced.
Importance:
High
Comprehensive boxed warnings and contraindications not presented; label requires explicit warnings.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Label acknowledges significant toxicity risks (hepatotoxicity, myelosuppression, pulmonary toxicity) that vary with dose and patient factors; overall risk in the evaluated content appears moderate due to dosing context.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Missing contraindications and boxed warnings; pregnancy/pediatric safety not addressed; insufficient coverage of monitoring cadence.
Suggested Improvement
Add explicit contraindications and boxed warnings with precise label citations; include pregnancy and pediatric safety statements; provide comprehensive dosing safety details (leucovorin rescue, folic acid interactions) and monitoring cadence; ensure patient education statements reflect label language with direct citations.